IBERE PHARMACEUTICALS's ticker is IBERWS and the CUSIP is G46843119. A total of 40 filers reported holding IBERE PHARMACEUTICALS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2 | -100.0% | 200,000 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $20,000 | +25.0% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $16,000 | -60.0% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $40,000 | -63.0% | 200,000 | 0.0% | 0.00% | -75.0% |
| Q4 2021 | $108,000 | -10.0% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $120,000 | -21.1% | 200,000 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $152,000 | – | 200,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynwood Capital Management Inc. | 9,800 | $108,054 | 0.10% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |